33 results on '"Scheiflinger, F"'
Search Results
2. Development of an automated VWF:RCo assay for measuring plasma samples with low activity: PO-MO-256
3. ADAMTS13 cleavage of recombinant human Willebrand factor in severe VWD patients: FP-TU-04.3-6
4. Efficacy of a recombinant ADAMTS13 in a mouse model of thrombotic thrombocytopenic purpura: PO-TU-269
5. Preclinical safety pharmacology of a PEGylated variant of recombinant factor VIII: PO-TU-173
6. Single-dose pharmacokinetics of a PEGylated variant of recombinant FVIII in factor VIII ko mice, rats, and macaques: PO-TU-175
7. Pharmacokinetics of a recombinant factor VIIa in factor VIII ko mice, rats, and macaques: PO-TU-174
8. Mode of action for anticoagulant activities of non-anticoagulant sulfated polysaccharides: PO-TU-132
9. BAX 499 restores clot formation to normal levels and reduces fibrinolysis in lysis-induced FVIII-inhibited whole blood: PO-TU-133
10. Successful immune tolerance induction is associated with a shift from FVIII-specific Th17-like pro-inflammatory immune profiles to FVIII-specific antiinflammatory immune profiles in a patient with hemophilia A and FVIII inhibitors: PO-WE-106
11. FVIII Specific CD4+ T Cell Epitopes that Drive Immune Responses to Human FVIII in Humanized HLA-DRB1*1501 Transgenic Hemophilic Mice Bind to Multiple Human HLA-DRB1* Proteins: FP-WE-01.1-4
12. Functional characterization of BAX 855, a PEGylated recombinant FVIII: PO-TU-063
13. Structural characterization of BAX 855, a PEGylated recombinant FVIII: PO-TU-065
14. Safety of BAX 855, a polyethylene glycol (PEG) conjugated full-length recombinant factor VIII product: PO-TU-068
15. Establishment of a manufacturing process for recombinant human ADAMTS13 retaining high specific activity: PO-TU-059
16. Characterization of BAX 326 a recombinant human factor IX drug candidate: PO-TU-067
17. Characterization of BAX 817, a recombinant FVIIa drug candidate: PO-TU-066
18. Influence of expression of recombinant human ADAMTS13 in cell lines from different species on its glycosylation pattern and pharmacokinetics: PO-TU-058
19. Development of a large-scale production process for BAX 855, a PEGylated rFVIII product: PO-TU-062
20. Susceptibility of von Willebrand factor from different mammalian species to cleavage by human recombinant ADAMTS13: PO-TU-060
21. Assessment of preclinical safety for BAX 326, Baxterʼs recombinant human factor IX: PO-TU-064
22. 2D-DIGE as a tool to analyze lot-to-lot consistency of complex therapeutic products such as BAX 855, a PEGylated recombinant FVIII: PO-TU-057
23. Efficacy of a new recombinant factor VIIa in animal models of hemophilia: PO-TU-049
24. Efficacy of a recombinant factor IX in mouse models of hemophilia B: PO-TU-048
25. Absorption, metabolism, distribution, and excretion of a PEGylated variant of recombinant factor FVIII following intravenous administration to rats: PO-TU-039
26. Safety of a PEGylated variant of recombinant factor VIII after repeated application in rats and macaques: PO-TU-038
27. Repeated application of a new recombinant factor IX in rats and macaques: PO-TU-036
28. Preclinical safety of a new recombinant factor VIIa: PO-TU-037
29. Safety of polyethylene glycol (PEG) in biopharmaceuticals: Focus on PEGrFVIII: FP-MO-03.2-4
30. Does PEGylated factor VIII induce antibodies against PEG?: FP-MO-03.2-5
31. Procoagulant activity of sulfated polysaccharides: 25P06
32. Pro-coagulant activity of Laminaria japonica derived fucoid (BAX513) depends on the interaction with the C-terminus of tissue factor pathway inhibitor: 09P12
33. The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.